Nalaganje...
Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
FKB327 was approved by the European Medicines Agency as a biosimilar to European‐authorized adalimumab (Humira(®); AbbVie Inc). Adalimumab is a monoclonal antibody, binding and inhibiting tumor necrosis factor (TNF)‐α with use indicated for several immune‐mediated, chronic, and inflammatory disorder...
Shranjeno v:
| izdano v: | Pharmacol Res Perspect |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7272391/ https://ncbi.nlm.nih.gov/pubmed/32500668 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.604 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|